Minor cannabinoid
CBN (Cannabinol)
The app lists a 10-hour half-life for cannabinol (CBN); the sources read give no CBN half-life, and a 2026 trial in 20 adults with insomnia found no significant change in wake after sleep onset, while 300 mg reduced sleep onset latency.1
CBN (Cannabinol) after one dose: 50% at ~10 h, 25% at 20 h, 12.5% at 30 h.
Drawn from the half-life in the app's model, ~10 h. The model's figures
- Compound
- CBN (Cannabinol)
- Symbol
- CBN
- Family
- Supplements
- Parts
- 12
- References
- 10
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Cannabinol (CBN) is a minor phytocannabinoid that, in the words of one 2026 review, "arises principally through oxidative transformation of THC during plant aging, processing and storage".7 A 2021 review by Corroon adds that CBN concentrations in plant material and extracts "are low, but increase over time as THC is exposed to light, oxygen, and heat".6 The app lists CBN as an oral cannabinoid supplement and grades its evidence as emerging; the sleep trials below enrolled between 20 and 1,793 adults, and one of them was sponsored by the company Canopy Growth Corporation. CBN is marketed for sleep, and Corroon notes that marketers "have claimed on websites, marketing materials, and product labels that cannabinol (CBN) has unique sleep-promoting effects".6 Pita and colleagues write that "the earlier reputation of CBN as a sleep aid substantially preceded controlled CBN-specific evidence".7 No DailyMed drug label for cannabinol was identified in a search on 16 November 2026.
How it works
Sources in this part
Corroon reports that CBN "is a partial agonist of the CB1 receptor with a lesser affinity than THC (CBN: Ki at CB1=211.2 nM vs. THC Ki at CB1=21 nM)".6 Pita and colleagues describe assay-dependent findings: one group found "low partial agonist activity of CBN at human CB1 receptors (Emax 29 ± 3%)", while another "reported no CB1 activation by CBN".7 They add that "assay platform, receptor expression, readout and concentration can materially alter apparent cannabinoid pharmacology".7 Corroon, in 2021, calls CB1 partial agonism a "plausible mechanism" for sleep effects but concludes that "there is insufficient published evidence to support sleep-related claims".6 These receptor findings come from cell assays and a review of preclinical work, not from measurements in people taking CBN.6,7
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~10 h
- Bioavailability
- 25%
- Typical dose
- 5–25 mg/dose
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
The second column holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~10 h | No CBN half-life figure was located in the sources read.1,7 |
| Bioavailability | 25% | The 2026 CUPID trial's discussion cites "low oral bioavailability (4%–19%)" with references to Huestis 2005, 2007 and Jung et al. 2022, in a passage on possible accumulation with repeated dosing; Pita and colleagues write that an absolute oral CBN estimate "cannot be assigned from the studies synthesized here" and that "Results for oral CBD cannot be used as numerical CBN bioavailability estimates".1,7 |
| Time to peak | ~2 h | No time to peak was reported in the sources read; the CUPID registry entry describes a "single fixed dose administered 2 hours prior to habitual sleep onset", which is a dosing schedule, not a measured peak.2 |
| Duration | ~8 h | No duration of effect was reported in the sources read. |
In CUPID, plasma was sampled before dosing and after waking. The authors report that "CBN and its metabolites were detected" after waking in the 30 mg and 300 mg arms, and that no cannabinoids or major phase I metabolites were detected before dosing.1 The same authors write that "pharmacokinetic studies of oral CBN isolate are needed".1 Pita and colleagues describe CBN as "highly lipophilic and poorly water soluble", characteristics that "complicate oral delivery and may produce variable absorption".7 The app's half-life, bioavailability, time to peak and duration are therefore not backed by a CBN-specific figure in the sources read.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Lavender and colleagues (CUPID), Journal of Sleep Research 20261 | Randomised, double-blind, placebo-controlled, three-arm, single-night crossover; Lambert Initiative funded1 | 20 adults aged 25-65 with physician-diagnosed insomnia disorder, all analysed1 | Single 2 mL oral dose of 30 mg or 300 mg CBN or placebo, 2-week washout1 | WASO unchanged (300 mg: -6.3 min, 95% CI -18.2 to +5.5, p = 0.29; 30 mg: -4.0 min, p = 0.50); 300 mg reduced sleep onset latency (p = 0.004); no serious adverse events, 246 mild AEs (91 on 300 mg, 73 on 30 mg, 82 on placebo) reported by 20/20 participants1 |
| Bonn-Miller and colleagues, Experimental and Clinical Psychopharmacology 20243 | Double-blind, randomised, placebo-controlled, parallel groups; Canopy Growth funded3,4 | 293 adults aged 18-55 who rated their sleep quality as "very poor" or "poor" (modified intent-to-treat)3 | 20 mg CBN, alone or with 10, 20 or 100 mg CBD, for 7 nights3 | Sleep quality (primary): OR 2.26, 95% CI 0.93 to 5.52, p = .082 for 20 mg CBN; awakenings and sleep disturbance reduced; no difference for sleep onset latency, WASO or daytime fatigue3 |
| Saleska and colleagues, Journal of the American Nutrition Association 20245 | Double-blind randomised trial of six capsule products against a 15 mg CBD isolate; authors from Radicle Science and academic centres5 | 1,793 adults with symptoms of sleep disturbance5 | 4-week supply; CBN 15 mg combined with CBD, with or without CBC, or with melatonin5 | No significant difference in effect between 15 mg CBD isolate and formulations with 15 mg CBD and 15 mg CBN; 12% of participants reported a side effect, none severe5 |
The registry search returned 19 ClinicalTrials.gov records for "cannabinol", including the CUPID and Canopy trials above and several trials of other cannabinoid products or conditions. A Corroon review of PubMed to January 2021 reported that "published clinical trials investigating associations between CBN and validated sleep questionnaires and/or formal polysomnography were not identified", so the three trials above are later than that search.6
Deeper analysis: CUPID (Lavender and colleagues, 2026)
Lavender and colleagues, from the Woolcock Institute of Medical Research and the University of Sydney, reported the CUPID trial in the Journal of Sleep Research in 2026.1 The trial gave 20 adults with insomnia disorder a single 2 mL oral dose of 30 mg or 300 mg CBN or matched placebo on three separate nights, with a 2-week washout; 17 were female and 3 male, and all 20 completed the protocol.1 The registry entry describes the CBN as an oral formulation "suspended in medium chain triglycerides (MCT) oil".2 The primary outcome was wake after sleep onset (WASO) measured by overnight polysomnography, and the authors report that "Cannabinol did not significantly change WASO (300 mg: -6.3 min [95% CI: -18.2, +5.5], p = 0.29, dz = -0.22; 30 mg: -4.0 min [-15.9, +7.9], p = 0.50, dz = 0.11)".1 Among secondary and tertiary outcomes, 300 mg CBN "reduced sleep onset latency (−7.0 min [−11.6, −2.3], p = 0.004, dz = −0.74)", while 30 mg CBN showed no change in that measure.1 The 300 mg dose also increased N2 sleep proportion and subjective sleep quality and reduced an EEG arousal index, and neither dose changed the proportion of wake, N1, N3 or REM sleep.1 On next-day measures, the authors report that "CBN did not change lateral vehicular control" in a simulated drive, while "some longitudinal vehicular control measures increased with 300 mg CBN".1 They also report a significant increase in subjective drug effect on the 'feel effect' subscale (1 h only) and the 'like effect' subscale (next day) with 300 mg, with no change to other subscales, and that Psychomotor Vigilance Test reaction time (time 2) "increased with 300 mg CBN".1 Of 54 safety outcomes assessed per treatment arm, "3 and 7 differed from placebo with 30 mg and 300 mg CBN, respectively".1 The paper reports that overnight procedural memory consolidation and anterior-posterior postural sway decreased with 30 mg CBN, and that next-day mood disturbance was significantly reduced with both doses.1 The authors list as limitations "the small sample size, large number of study outcomes", a single-night design, and the exclusion of high-risk individuals; they write that "This trial does not provide direct evidence that CBN is effective for insomnia in routine clinical care".1 The authors also note a fixed-dose design "which may have caused impairment in some individuals", that they "did not standardize for menstrual cycle", and that "the potential influence of placebo effects cannot be ruled out" for the subjective sleep quality results.1 Funding came from the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, and the paper states that "Lambert Initiative members played a role in the design, conduct, and reporting of the study".1 Ties disclosed: "I.S.M. is the Academic Director of the Lambert Initiative for Cannabinoid Therapeutics" and "J.C.A. is Deputy Academic Director of the Lambert Initiative for Cannabinoid Therapeutics, University of Sydney", both authors on the paper, and several authors report consulting fees from Medicinal Cannabis Industry Australia.1 The investigational product "was purchased from Medropharm" through BOD Australia, which the paper says was not involved in the conception, design or conduct of the study.1 The study was sponsored by the Woolcock Institute of Medical Research, and the paper's conflict statement adds that the Woolcock Institute Sleep and Chronobiology Research Group has received research support from several companies, including BOD Australia.1
Deeper analysis: the Canopy Growth sleep-quality trial (Bonn-Miller and colleagues, 2024)
Bonn-Miller and colleagues, whose listed affiliations are Canopy Growth Corporation and, for one author, Wana Brands, reported the trial in Experimental and Clinical Psychopharmacology in 2024.3 The PubMed record lists "Canopy Growth Corporation" under grants, and the registry entry names Canopy Growth Corporation as lead sponsor, class industry.3,4 Adults aged 18-55 who rated their sleep quality as "very poor" or "poor" were randomised to placebo, 20 mg CBN, or 20 mg CBN with 10, 20 or 100 mg CBD for seven consecutive nights.3 The registry entry gives enrolment of 301 and describes each arm as 2 gummies, with 10 mg CBN per gummy in the CBN-only arm; the analysis reported in the journal included 293.4,3 The primary endpoint was sleep quality; secondary endpoints included sleep onset latency, number of awakenings, wake after sleep onset, overall sleep disturbance and daytime fatigue.3 Against placebo, 20 mg CBN "demonstrated a nonsignificant but potentially meaningful effect on sleep quality (OR [95% CI] = 2.26 [0.93, 5.52], p = .082)" and "significantly reduced number of awakenings (95% CI [-0.96, -0.05], p = .025) and overall sleep disturbance (95% CI [-2.59, -0.14], p = .023)".3 "There was no difference from placebo among any group for sleep onset latency, WASO, or daytime fatigue", and "The addition of CBD did not positively augment CBN treatment effects".3 The PubMed record for the trial contains no adverse event counts and no limitations section, so neither is reported; the registry entry shows "Has Results: undefined".3,4
Deeper analysis: six-product comparison (Saleska and colleagues, 2024)
Saleska and colleagues, with authors at Radicle Science and at the University of Pittsburgh, the University of Maryland, UCLA and Scripps Clinic, reported the trial in the Journal of the American Nutrition Association in 2024.5 The trial randomised 1,793 adults with sleep disturbance to a 4-week supply of one of six capsule products containing 15 mg CBD or 5 mg melatonin, alone or with minor cannabinoids, and measured sleep disturbance weekly with PROMIS Sleep Disturbance SF 8A.5 All formulations were associated with improvement within groups, and "Most participants (56% to 75%) across all formulations experienced a clinically important improvement in their sleep quality".5 The comparison that bears on CBN is the null one: "There were no significant differences in effect, however, between 15 mg CBD isolate and formulations containing 15 mg CBD and 15 mg cannabinol (CBN), alone or in combination with 5 mg cannabichromene (CBC)".5 The authors conclude that "the addition of low doses of CBN and CBC may not improve the effect of formulations containing CBD or melatonin isolate".5 They report "All formulations exhibited a favorable safety profile (12% of participants reported a side effect and none were severe)".5 No CBN-only arm is described in the PubMed record read, so the trial cannot be read as a test of CBN alone; the record has no limitations section or funding statement, so neither is reported here.5
Doses reported in studies and on labels
No drug label for cannabinol was identified, so the table lists doses used in trials and, for marketed products, a review's figure.
| Source | People and n | Dose and route | Length | Comparator |
|---|---|---|---|---|
| The app's typical dose | Not stated | 5–25 mg per dose, oral | Not stated | Not stated |
| Lavender and colleagues 20261 | 20 adults with insomnia disorder | 30 mg or 300 mg CBN, single 2 mL oral dose | One night per dose, 2-week washout | Matched placebo |
| Bonn-Miller and colleagues 20243,4 | 293 analysed (301 enrolled per registry) | 20 mg CBN alone or with 10, 20 or 100 mg CBD; gummies per registry | 7 nights | Placebo |
| Saleska and colleagues 20245 | 1,793 adults with sleep disturbance across six products | 15 mg CBN with 15 mg CBD, with or without 5 mg CBC; capsules | 4 weeks | 15 mg CBD isolate |
| Marketed products, Corroon review 20216 | Not applicable | "typically ≤5 mg" in cannabis products marketed for sleep | Not applicable | Not applicable |
Side effects reported
Sources in this part
In CUPID, "No serious AEs such as unplanned hospitalizations or deaths occurred" and "There were no participant withdrawals due to AEs".1 The authors report "246 mild AEs (91 in 300 mg CBN, 73 in 30 mg CBN, and 82 in placebo arms) were reported by 20/20 participants, with one moderate AE reported (in the placebo arm)".1 The most common were standardised questionnaire items such as fatigue, drowsiness, lethargy, dry mouth, dizziness, nausea or vomiting, and "drunk/intoxicated".1 The authors write that participants "reported mild subjective drug effects with 300 mg CBN".1 In the six-product trial, 12% of participants reported a side effect and none were severe, across formulations that also contained CBD or melatonin.5 The Canopy Growth trial's PubMed record gives no adverse event figures.3
Regulatory and anti-doping status
Sources in this part
The World Anti-Doping Agency's 2026 Prohibited List section on cannabinoids is headed "PROHIBITED IN-COMPETITION" and states "All natural and synthetic cannabinoids are prohibited, e.g.".10 The list gives cannabis products, natural and synthetic tetrahydrocannabinols and synthetic cannabinoids that mimic the effects of THC as examples, and gives cannabidiol as the exception.10 CBN is not named in the text of the 2026 list that was read; a later list was not read.10 In the United States, Corroon wrote in 2021 that "as a constituent in cannabis, CBN is deemed a Schedule I controlled substance, per the definition of marijuana in the Controlled Substances Act of 1970".6 The same review states that "As a constituent in hemp, it is not a controlled substance at all, per the Agricultural Improvement Act of 2018".6 That is a 2021 reading by one author, and no regulator's text on CBN was read for this review of the sources.
What is not known
No CBN-specific half-life, time to peak or absolute oral bioavailability was located in the sources read, so the app's figures of 10 hours, 2 hours and 25% have no matching source figure here.7,1 The three sleep trials above were single-night or up to 4 weeks long, and the CUPID authors write that the "study duration was insufficient to fully evaluate" long-term safety.1,3,5 The trials with several cannabinoids cannot separate CBN from its co-ingredients. A 10-day crossover pilot in 20 adults with subthreshold insomnia gave a soft gel with "6 mg cannabinol, 10 mg cannabidiol, and 90 mg of a proprietary food-grade terpene blend" and also THC, so its results cannot be read as results for CBN alone.9 Interaction data are preclinical: Anderson and colleagues, with authors at the University of Sydney and Northwestern University, report that CBN "increased the apparent oral bioavailability of melatonin in mice with a four-fold increase in the plasma melatonin exposure".8 Pita and colleagues add that this "is a preclinical interaction signal, not a demonstrated fourfold effect in humans".7 The Anderson paper lists a Lambert grant, the same philanthropic name as the funder of CUPID, and its last author is also an author of CUPID.8,1 No trial of CBN alone in a population other than adults with insomnia symptoms or sleep disturbance was identified in the searches run.
Frequently asked questions
What is the half-life of CBN?
What is the bioavailability of CBN?
Is CBN banned by WADA?
Is CBN a controlled substance in the US?
Corroon wrote in 2021 that CBN from cannabis is deemed a Schedule I controlled substance, and CBN from hemp is not a controlled substance.6
Is CBN an approved drug?
No DailyMed label for cannabinol was identified in a search on 16 November 2026.
Where does CBN come from?
CBN arises principally through oxidative transformation of THC during plant aging, processing and storage.7
Did CBN change sleep in clinical trials?
In the 20-adult CUPID trial, CBN did not significantly change wake after sleep onset, while 300 mg reduced sleep onset latency.1 In a 293-adult trial with a Canopy Growth Corporation grant and authors affiliated with that company, 20 mg CBN gave a nonsignificant effect on sleep quality (p = .082) and fewer awakenings, with no difference in sleep onset latency.3
Does CBN interact with melatonin?
A mouse study found CBN increased melatonin exposure about four-fold; no human interaction study was identified.8
Guides, tools and comparisons
References
- Lavender IG, et al. Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial. J Sleep Res 2026. PMID 41698831
- Woolcock Institute of Medical Research. Cannabinol Use in Patients With Insomnia Disorder (CUPID). ClinicalTrials.gov NCT05344170. NCT05344170
- Bonn-Miller MO, et al. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Exp Clin Psychopharmacol 2024. PMID 37796540
- Canopy Growth Corporation. A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality. ClinicalTrials.gov NCT05839964. NCT05839964
- Saleska JL, et al. The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. J Am Nutr Assoc 2024. PMID 37162192
- Corroon J. Cannabinol and Sleep: Separating Fact from Fiction. Cannabis Cannabinoid Res 2021. PMID 34468204
- Pita D, et al. Cannabinol for Sleep and Insomnia: A Critical Narrative Review and an Olive-Derived Polyphenol Combination Hypothesis. Nutrients 2026. PMID 43030286
- Anderson LL, et al. Preclinical Evidence for a Drug-Drug Interaction Between Cannabinol and Melatonin. Basic Clin Pharmacol Toxicol 2025. PMID 39722474
- Hausenblas H, et al. Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. Health Sci Rep 2025. PMID 39980821
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list